Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

Shortages of tirzepatide, sold as a diabetes drug (Mounjaro) and a weight-loss medication (Zepbound), have fueled demand for compounding pharmacies to make their own versions of the medicine, which ...

In a reversal, the FDA is reconsidering its decision to end the shortage status of tirzepatide, after a recent lawsuit and intense public pressure, The Washington Post reported Oct. 21.

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

Discover why Sagimet Biosciences' Denifanstat is a top contender in treating MASH, with FDA designation and strong financials ...

If tirzepatide remains off the FDA's drug shortage list, compounding pharmacies must cease the production of these medications on any significant scale, according to gastroenterologist and obesity ...

But when the FDA announced on Oct. 2 that the shortage of tirzepatide had ended, that meant compounding pharmacies had to stop making it. For now though, according to the recent court filing ...